{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-26-000068","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-09-21T20:10:47+00:00","discovered_at":"2026-09-21T20:12:02.675695+00:00","generated_at":"2026-09-21T20:12:24.000907+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Brad Campbell named Travere CEO, succeeding Eric Dube effective Dec 1","bullets":["Eric Dube steps down as Travere President/CEO and Director effective Dec 1, 2026, remaining Executive Advisor until Feb 15, 2027.","Bradley Campbell (ex-CEO of Amicus until its Apr 2026 BioMarin acquisition) starts as President/CEO and Director on Dec 1, 2026.","Campbell receives $1.0M base salary, 85% target bonus, $500k expense payment, and ~$16.5M initial equity (option + RSUs); ~$3.75M performance RSU in 2027.","Dube keeps salary through Feb 2027, eligible for 75% 2026 bonus, but no 2027 bonus or new equity; performance RSUs cease vesting at separation."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-26-000068","json":"https://secwatch.observer/filing/0001438533-26-000068.json","markdown":"https://secwatch.observer/filing/0001438533-26-000068.md","text":"https://secwatch.observer/filing/0001438533-26-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000068/0001438533-26-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000068/tvtx-20260921.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-21T20:12:24.000907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a0c8d3a4a","claim":"Bradley L. Campbell was appointed as President and Chief Executive Officer at Travere Therapeutics, Inc..","evidence_excerpt":"Bradley L. Campbell has been named as Dr. Dube’s successor with his appointment as President and Chief Executive Officer and as a member of the Board of Directors to be effective as of the Officer Resignation Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000068/0001438533-26-000068-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"75b1470181","claim":"Eric Dube was appointed as Executive Advisor at Travere Therapeutics, Inc..","evidence_excerpt":"As discussed in greater detail below, Dr. Dube has agreed to continue with the Company as Executive Advisor through February 15, 2027, to facilitate a smooth transition of responsibilities and has agreed to serve as Consultant to the Chief Executive Officer for a period following the employment transition.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000068/0001438533-26-000068-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"agreed to continue as"},{"label":"Role","value":"Executive Advisor"}],"fact_type":"executive_change"},{"claim_id":"be852109ad","claim":"Bradley L. Campbell was appointed as Member of the Board of Directors at Travere Therapeutics, Inc..","evidence_excerpt":"Bradley L. Campbell has been named as Dr. Dube’s successor with his appointment as President and Chief Executive Officer and as a member of the Board of Directors to be effective as of the Officer Resignation Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000068/0001438533-26-000068-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}